UBS AM
NAMS icon

UBS AM’s NewAmsterdam Pharma NAMS Stock Holding History

UBS AM’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-285,285
Closed -$9.13M – 3822
2026
Q1 		$9.13M Buy
285,285
+20,086
+8% +$654K ﹤0.01% 1228
2025
Q4 		$9.3M Buy
+265,199
New +$9.65M ﹤0.01% 1150
2025
Q3 		– Sell
-320,804
Closed -$5.81M – 2479
2025
Q2 		$5.81M Buy
320,804
+32,670
+11% +$596K ﹤0.01% 1641
2025
Q1 		$5.9M Buy
288,134
+34,563
+14% +$768K ﹤0.01% 1488
2024
Q4 		$6.52M Buy
253,571
+14,288
+6% +$303K ﹤0.01% 1468
2024
Q3 		$3.97M Buy
239,283
+221,305
+1,231% +$3.83M ﹤0.01% 1694
2024
Q2 		$345K Buy
+17,978
New +$361K ﹤0.01% 2701

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

UBS AM's NAMS Position: Q2 2026 in Review

UBS AM sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 285,285 shares — an estimated $9.13M sold.

UBS AM first reported a position in NAMS in Q2 2024 and held it in 7 quarters. The position peaked at $9.3M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • UBS AM reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
  • UBS AM sold 285,285 NewAmsterdam Pharma shares in Q2 2026, an estimated $9.13M.
  • UBS AM first reported a position in NewAmsterdam Pharma in Q2 2024 and held it in 7 quarters.
  • UBS AM's NewAmsterdam Pharma position peaked at $9.3M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.